Janssen hands NASH candidate back to Arrowhead
16 Feb 2023
Phase 1License out/inGene TherapysiRNA
Arrowhead Pharmaceuticals announced that Janssen Pharmaceuticals has handed back the rights to an experimental treatment for non-alcoholic steatohepatitis (NASH) — a type of liver disease for which there are currently no FDA approved drugs.
ARO-PNPLA3, formerly called JNJ-75220795, was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen. Under the deal, Janssen obtained a worldwide license for Arrowhead’s experimental Hepatitis B drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, using Arrowhead's gene-silencing technology. The deal had a combined potential value of over $3.7 billion for Arrowhead.
Now, the California-based company has now regained control of one of the RNAi drugs from the deal — ARO-PNPLA3 — currently in phase 1 trials. ARO-PNPLA3 is an investigational RNAi therapeutic developed using Arrowhead’s proprietary TRiMTM platform and designed to reduce liver expression of patatin-like phospholipase domain containing protein 3 (PNPLA3) as a potential treatment for patients with NASH.
NASH is a subgroup of non-alcoholic fatty liver disease. Although there are many investigational drugs in clinical study, there are no drugs specifically approved for the treatment of NASH.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.